{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:59:41Z","timestamp":1787806781091,"version":"build-2784847793"},"reference-count":53,"publisher":"Pharmaceutical Society of Japan","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1248\/bpb.b18-00923","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T22:08:23Z","timestamp":1559340503000},"page":"929-936","source":"Crossref","is-referenced-by-count":13,"title":["Effects of Zoledronate on Local and Systemic Production of IL-1\u03b2, IL-18, and TNF-\u03b1 in Mice and Augmentation by Lipopolysaccharide"],"prefix":"10.1248","volume":"42","author":[{"given":"Hiromi","family":"Funayama","sequence":"first","affiliation":[{"name":"Department of Pediatric Dentistry, Tsurumi University School of Dental Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Tashima","sequence":"additional","affiliation":[{"name":"Department of Pediatric Dentistry, Tsurumi University School of Dental Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Okada","sequence":"additional","affiliation":[{"name":"Division of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Tohoku University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Division of Cell Biology, Department of Pharmaceutical Sciences, School of Pharmacy, International University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yagi","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Department of Pharmaceutical Sciences, School of Pharmacy, International University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tada","sequence":"additional","affiliation":[{"name":"Division of Oral Molecular Regulation, Graduate School of Dentistry, Tohoku University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Wakita","sequence":"additional","affiliation":[{"name":"Section of Anesthesiology and Clinical Physiology, Department of Oral Restitution, Division of Oral Health Sciences, Graduate School, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Asada","sequence":"additional","affiliation":[{"name":"Department of Pediatric Dentistry, Tsurumi University School of Dental Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Endo","sequence":"additional","affiliation":[{"name":"Division of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Tohoku University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. <i>Clin. Cancer Res.<\/i>, <b>12<\/b>, 6222s\u20136230s (2006)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. <i>Drug Saf.<\/i>, <b>14<\/b>, 158\u2013170 (1996).","DOI":"10.2165\/00002018-199614030-00003"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. <i>J. Oral Maxillofac. Surg.<\/i>, <b>67<\/b> (Suppl.), 13\u201318 (2009).","DOI":"10.1016\/j.joms.2008.10.005"},{"key":"4","unstructured":"4) Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. <i>Ann. Intern. Med.<\/i>, <b>144<\/b>, 753\u2013761 (2006)."},{"key":"5","unstructured":"5) Yamaguchi K, Oizumi T, Funayama H, Kawamura H, Sugawara S, Endo Y. Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale. <i>J. Oral Maxillofac. Surg.<\/i>, <b>68<\/b>, 889\u2013897 (2010)."},{"key":"6","unstructured":"6) Oizumi T, Funayama H, Yamaguchi K, Yokoyama M, Takahashi H, Yamamoto M, Kuroishi T, Kumamoto H, Sasaki K, Kawamura H, Sugawara S, Endo Y. Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. <i>J. Oral Maxillofac. Surg.<\/i>, <b>68<\/b>, 1043\u20131054 (2010)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. <i>Calcif. Tissue Int.<\/i>, <b>38<\/b>, 342\u2013349 (1986).","DOI":"10.1007\/BF02555748"},{"key":"8","unstructured":"8) Oizumi T, Yamaguchi K, Funayama H, Kuroishi T, Kawamura H, Sugawara S, Endo Y. Necrotic actions of nitrogen-containing bisphosphonates and their inhibition by clodronate, a non-nitrogen-containing bisphosphonate in mice: potential for utilization of clodronate as a combination drug with a nitrogen-containing bisphosphonate. <i>Basic Clin. Pharmacol. Toxicol.<\/i>, <b>104<\/b>, 384\u2013392 (2009)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Okada S, Kiyama T, Sato E, Tanaka Y, Oizumi T, Kuroishi T, Takahashi T, Sasaki K, Sugawara S, Endo Y. Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice. <i>Tohoku J. Exp. Med.<\/i>, <b>231<\/b>, 145\u2013158 (2013).","DOI":"10.1620\/tjem.231.145"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kiyama T, Okada S, Tanaka Y, Kim S, Bando K, Hasegawa M, Yamaguchi K, Takano-Yamamoto T, Sasaki K, Sugawara S, Endo Y. Inflammatory and necrotic effects of minodronate, a nitrogen-containing bisphosphonate, in mice. <i>Tohoku J. Exp. Med.<\/i>, <b>230<\/b>, 141\u2013149 (2013).","DOI":"10.1620\/tjem.230.141"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Scheper MA, Badros A, Salama AR, Warburton G, Cullen KJ, Weikel DS, Meiller TF. A novel bioassay model to determine clinically significant bisphosphonate levels. <i>Support. Care Cancer<\/i>, <b>17<\/b>, 1553\u20131557 (2009).","DOI":"10.1007\/s00520-009-0710-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Cornish J, Bava U, Callon KE, Bai J, Naot D, Reid IR. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. <i>Bone<\/i>, <b>49<\/b>, 710\u2013716 (2011).","DOI":"10.1016\/j.bone.2011.07.020"},{"key":"13","unstructured":"13) Cr\u00e9pin S, Laroche ML, Sarry B, Merle L. Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>66<\/b>, 547\u2013554 (2010)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Endo Y, Shibazaki M, Yamaguchi K, Nakamura M, Kosugi H. Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. <i>Br. J. Pharmacol.<\/i>, <b>126<\/b>, 903\u2013910 (1999).","DOI":"10.1038\/sj.bjp.0702367"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Funayama H, Ohsako M, Monma Y, Mayanagi H, Sugawara S, Endo Y. Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate. <i>Calcif. Tissue Int.<\/i>, <b>76<\/b>, 448\u2013457 (2005).","DOI":"10.1007\/s00223-004-0180-3"},{"key":"16","unstructured":"16) Shima K, Tsuchiya M, Oizumi T, Takano-Yamamoto T, Sugawara S, Endo Y. Inflammatory effects of nitrogen-containing bisphosphonates (N-BPs): modulation by non-N-BPs. <i>Biol. Pharm. Bull.<\/i>, <b>40<\/b>, 25\u201333 (2017)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Rogers MJ, Crockett JC, Coxon FP, M\u00f6nkk\u00f6nen J. Biochemical and molecular mechanisms of action of bisphosphonates. <i>Bone<\/i>, <b>49<\/b>, 34\u201341 (2011).","DOI":"10.1016\/j.bone.2010.11.008"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kiyama T, Tsuchiya M, Okada S, Oizumi T, Yamaguchi K, Sasaki K, Sugawara S, Endo Y. Phosphonocarboxylates can protect mice against the inflammatory and necrotic side effects of nitrogen-containing bisphosphonates by inhibiting their entry into cells <i>via<\/i> phosphate transporters. <i>Biol. Pharm. Bull.<\/i>, <b>39<\/b>, 712\u2013720 (2016).","DOI":"10.1248\/bpb.b15-00770"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Endo Y, Kumamoto H, Nakamura M, Sugawara S, Takano-Yamamoto T, Sasaki K, Takahashi T. Underlying mechanisms and therapeutic strategies for bisphosphonate-related osteonecrosis of the jaw (BRONJ). <i>Biol. Pharm. Bull.<\/i>, <b>40<\/b>, 739\u2013750 (2017).","DOI":"10.1248\/bpb.b16-01020"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. <i>Nat. Rev. Drug Discov.<\/i>, <b>11<\/b>, 633\u2013652 (2012).","DOI":"10.1038\/nrd3800"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Sugawara S, Shibazaki M, Takada H, Kosugi H, Endo Y. Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor alpha in mice. <i>Br. J. Pharmacol.<\/i>, <b>125<\/b>, 735\u2013740 (1998).","DOI":"10.1038\/sj.bjp.0702151"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Yamaguchi K, Motegi K, Iwakura Y, Endo Y. Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. <i>Br. J. Pharmacol.<\/i>, <b>130<\/b>, 1646\u20131654 (2000).","DOI":"10.1038\/sj.bjp.0703460"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Deng X, Yu Z, Funayama H, Shoji N, Sasano T, Iwakura Y, Sugawara S, Endo Y. Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate. <i>Toxicol. Appl. Pharmacol.<\/i>, <b>213<\/b>, 64\u201373 (2006).","DOI":"10.1016\/j.taap.2005.09.005"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Deng X, Tamai R, Endo Y, Kiyoura Y. Alendronate augments interleukin-1beta release from macrophages infected with periodontal pathogenic bacteria through activation of caspase-1. <i>Toxicol. Appl. Pharmacol.<\/i>, <b>235<\/b>, 97\u2013104 (2009).","DOI":"10.1016\/j.taap.2008.11.005"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Shikama Y, Nagai Y, Okada S, Oizumi T, Shimauchi H, Sugawara S, Endo Y. Pro-IL-1\u03b2 accumulation in macrophages by alendronate and its prevention by clodronate. <i>Toxicol. Lett.<\/i>, <b>199<\/b>, 123\u2013128 (2010).","DOI":"10.1016\/j.toxlet.2010.08.013"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Aachoui Y, Sagulenko V, Miao EA, Stacey KJ. Inflammasome-mediated pyroptotic and apoptotic cell death, and defense against infection. <i>Curr. Opin. Microbiol.<\/i>, <b>16<\/b>, 319\u2013326 (2013).","DOI":"10.1016\/j.mib.2013.04.004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Galluzzi L, L\u00f3pez-Soto A, Kumar S, Kroemer G. Caspases connect cell-death signaling to organismal homeostasis. <i>Immunity<\/i>, <b>44<\/b>, 221\u2013231 (2016).","DOI":"10.1016\/j.immuni.2016.01.020"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Yuan J, Najafov A, Py BF. Roles of caspases in necrotic cell death. <i>Cell<\/i>, <b>167<\/b>, 1693\u20131704 (2016).","DOI":"10.1016\/j.cell.2016.11.047"},{"key":"29","unstructured":"29) Wallach D, Kang TB, Dillon CP, Green DR. Programmed necrosis in inflammation: toward identification of the effector molecules. <i>Science<\/i>, <b>352<\/b>, aaf2154 (2016)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. <i>Am. J. Clin. Nutr.<\/i>, <b>83<\/b>, 447S\u2013455S (2006).","DOI":"10.1093\/ajcn\/83.2.447S"},{"key":"31","unstructured":"31) Sollberger G, Strittmatter GE, Garstkiewicz M, Sand J, Beer HD. Caspase-1: the inflammasome and beyond. <i>Innate Immun<\/i>, <b>20<\/b>, 115\u2013125 (2014)."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Uchiyama R, Tsutsui H. Caspases as the key effectors of inflammatory responses against bacterial infection. <i>Arch. Immunol. Ther. Exp.<\/i> (Warsz), <b>63<\/b>, 1\u201313 (2015).","DOI":"10.1007\/s00005-014-0301-2"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Tamai R, Sugiyama A, Kiyoura Y. Alendronate regulates cytokine production induced by lipid A through nuclear factor-\u03baB and Smad3 activation in human gingival fibroblasts. <i>J. Periodontal Res.<\/i>, <b>46<\/b>, 13\u201320 (2011).","DOI":"10.1111\/j.1600-0765.2010.01302.x"},{"key":"34","unstructured":"34) Norton JT, Hayashi T, Crain B, Cho JS, Miller LS, Corr M, Carson DA. Cutting edge: nitrogen bisphosphonate-induced inflammation is dependent upon mast cells and IL-1. <i>J. Immunol.<\/i>, <b>188<\/b>, 2977\u20132980 (2012)."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Zhang Q, Yu W, Lee S, Xu Q, Naji A, Le AD. Bisphosphonate induces osteonecrosis of the jaw in diabetic mice <i>via<\/i> NLRP3\/caspase-1-dependent IL-1\u03b2 mechanism. <i>J. Bone Miner. Res.<\/i>, <b>30<\/b>, 2300\u20132312 (2015).","DOI":"10.1002\/jbmr.2577"},{"key":"36","unstructured":"36) Bagan J, Sheth CC, Soria JM, Margaix M, Bagan L. Bisphosphonates-related osteonecrosis of the jaws: a preliminary study of salivary interleukins. <i>J. Oral Pathol. Med.<\/i>, <b>42<\/b>, 405\u2013408 (2013)."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Tsao C, Darby I, Ebeling PR, Walsh K, O\u2019Brien-Simpson N, Reynolds E, Borromeo G. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. <i>J. Oral Maxillofac. Surg.<\/i>, <b>71<\/b>, 1360\u20131366 (2013).","DOI":"10.1016\/j.joms.2013.02.016"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. <i>Semin. Immunol.<\/i>, <b>25<\/b>, 439\u2013448 (2013).","DOI":"10.1016\/j.smim.2013.10.014"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Mandey SH, Kuijk LM, Frenkel J, Waterham HR. A role for geranylgeranylation in interleukin-1\u03b2 secretion. <i>Arthritis Rheum.<\/i>, <b>54<\/b>, 3690\u20133695 (2006).","DOI":"10.1002\/art.22194"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) van der Burgh R, Pervolaraki K, Turkenburg M, Waterham HR, Frenkel J, Boes M. Unprenylated RhoA contributes to IL-1\u03b2 hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity. <i>J. Biol. Chem.<\/i>, <b>289<\/b>, 27757\u201327765 (2014).","DOI":"10.1074\/jbc.M114.571810"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Montero MT, Hern\u00e1ndez O, Su\u00e1rez Y, Matilla J, Ferruelo AJ, Mart\u00ednez-Botas J, G\u00f3mez-Coronado D, Lasunci\u00f3n MA. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. <i>Atherosclerosis<\/i>, <b>153<\/b>, 303\u2013313 (2000).","DOI":"10.1016\/S0021-9150(00)00417-2"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Coward WR, Marei A, Yang A, Vasa-Nicotera MM, Chow SC. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. <i>J. Immunol.<\/i>, <b>176<\/b>, 5284\u20135292 (2006).","DOI":"10.4049\/jimmunol.176.9.5284"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Takahashi HK, Mori S, Iwagaki H, Yoshino T, Tanaka N, Nishibori M. Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells. <i>Clin. Immunol.<\/i>, <b>116<\/b>, 211\u2013216 (2005).","DOI":"10.1016\/j.clim.2005.04.007"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Takahashi HK, Mori S, Iwagaki H, Yoshino T, Tanaka N, Weitz-Schmidt G, Nishibori M. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes. <i>J. Leukoc. Biol.<\/i>, <b>77<\/b>, 400\u2013407 (2005).","DOI":"10.1189\/jlb.0904510"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Wankowicz Z, Megyeri P, Issekutz A. Synergy between tumour necrosis factor \u03b1 and interleukin-1 in the induction of polymorphonuclear leukocyte migration during inflammation. <i>J. Leukoc. Biol.<\/i>, <b>43<\/b>, 349\u2013356 (1988).","DOI":"10.1002\/jlb.43.4.349"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Vogel SN, Kaufman EN, Tate MD, Neta R. Recombinant interleukin-1 alpha and recombinant tumor necrosis factor alpha synergize <i>in vivo<\/i> to induce early endotoxin tolerance and associated hematopoietic changes. <i>Infect. Immun.<\/i>, <b>56<\/b>, 2650\u20132657 (1988).","DOI":"10.1128\/IAI.56.10.2650-2657.1988"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Endo Y. Induction of histidine and ornithine decarboxylase activities in mouse tissues by recombinant interleukin-1 and tumor necrosis factor. <i>Biochem. Pharmacol.<\/i>, <b>38<\/b>, 1287\u20131292 (1989).","DOI":"10.1016\/0006-2952(89)90335-3"},{"key":"48","unstructured":"48) Beck G, Habicht GS, Benach JL, Miller F. Interleukin 1: a common endogenous mediator of inflammation and the local Shwartzman reaction. <i>J. Immunol.<\/i>, <b>136<\/b>, 3025\u20133031 (1986)."},{"key":"49","unstructured":"49) Movat HZ, Burrowes CE, Cybulsky MI, Dinarello CA. Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury. <i>Am. J. Pathol.<\/i>, <b>129<\/b>, 463\u2013476 (1987)."},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Rothstein JL, Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>85<\/b>, 607\u2013611 (1988).","DOI":"10.1073\/pnas.85.2.607"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Vassalli P. The pathophysiology of tumor necrosis factors. <i>Annu. Rev. Immunol.<\/i>, <b>10<\/b>, 411\u2013452 (1992).","DOI":"10.1146\/annurev.iy.10.040192.002211"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Di Paolo NC, Shayakhmetov DM. Interleukin 1\u03b1 and the inflammatory process. <i>Nat. Immunol.<\/i>, <b>17<\/b>, 906\u2013913 (2016).","DOI":"10.1038\/ni.3503"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. <i>Immunol. Rev.<\/i>, <b>281<\/b>, 8\u201327 (2018).","DOI":"10.1111\/imr.12621"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/6\/42_b18-00923\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T17:36:03Z","timestamp":1608140163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/6\/42_b18-00923\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b18-00923","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}